

21/LG/SE/MAR/2022/GBSL

March 09, 2022

To
The Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001

To
The Manager
National Stock Exchange Of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code : 509079

Symbol : GUFICBIO

Sub: Press Release - Gufic Biosciences Limited forays into cancer immunology by undertaking research collaboration with Selvax Pty Ltd, a Company based in Australia


Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith a press release being issued by the Company on the captioned subject, the content of which is self-explanatory.

The same is submitted for public dissemination and your records.

Thanking You,

For Gufic Biosciences Limited



Ami N. Shah
Company Secretary
Mem No: A39579



Encl: As above



Gufic Biosciences Limited forays into Cancer Immunology by undertaking research collaboration with Selvax Pty Ltd, a company based in Australia

Mumbai, March 09, 2022

Gufic Biosciences Limited ("Gufic") is pleased to announce that it is entering into a research and collaboration agreement with M/s. Selvax Pty Ltd ("Selvax"), a biotechnology Company based in Perth, Western Australia, to accelerate the commercialization of Selvax's cancer immunotherapy treatment. M/s. Orbit Financial Capital, a boutique investment banking firm with a strong foothold in corporate finance, transaction advisory services, and debt syndication services, acts as the exclusive financial advisor to the transaction.

Under this initiative, Gufic will undertake mutually agreed development activities in return for the exclusive commercial rights for Selvax immunotherapy in India along with an equal share of future revenues that might be derived from future sales of the product in Europe, subject to the approvals received from the regulatory authorities in India and Europe, respectively.

Selvax's goal is to develop a safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours. It was formed following a breakthrough in cancer research where researchers at Curtin University West Australia, came to understand the sophisticated methods used by tumours to evade the body's immune system. This has allowed the research team of Selvax to develop a self-vaccine approach where the body's immune system is harnessed rather than hindered in treating cancer.

A major advantage of the Selvax technology is that it targets the tumour micro-environment in cancer cells and stimulates an immune response. This allows the technology to overcome major challenges previously faced with other cancer immunotherapies including poor response rates and potentially serious toxicity. It is envisaged that the successful development of the technology will provide novel cancer treatments for animals and humans.

Selvax considers Gufic as an ideal collaboration partner on account of Gufic's long track record of innovation and new drug development. Gufic continues its efforts to bring innovation in the medical field by expanding its portfolio in cancer immunotherapy, which is one of the most rapidly growing segments of the global pharmaceutical market.